On June 3, 2024, Novo Nordisk announced its ongoing share repurchase program which began on May 6, 2024, aiming to buy back up to DKK 2.2 billion worth of B shares by August 5, 2024, with a total of 632,545 shares purchased so far. The total share repurchase program has a budget of DKK 20 billion within a year starting from February 6, 2024, targeting chronic disease management.